Enovis (NYSE: ENOV) has recently received a number of price target changes and ratings updates:
- 10/12/2026 – Enovis had its price target lowered by Needham & Company LLC from $52.00 to $34.00. They now have a “buy” rating on the stock.
- 10/10/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.
- 10/5/2026 – Enovis had its “buy” rating reaffirmed by UBS Group AG. They now have a $44.00 price target on the stock.
- 9/28/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
- 9/20/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.
- 9/12/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
- 9/2/2026 – Enovis had its “market outperform” rating reaffirmed by Citigroup Inc..
- 9/2/2026 – Enovis had its price target lowered by Wells Fargo & Company from $39.00 to $33.00. They now have an “overweight” rating on the stock.
- 9/2/2026 – Enovis had its price target lowered by Citizens Jmp from $55.00 to $47.00. They now have a “market outperform” rating on the stock.
- 9/1/2026 – Enovis had its price target lowered by BTIG Research from $40.00 to $36.00. They now have a “buy” rating on the stock.
- 9/1/2026 – Enovis was given a new $27.00 price target by BMO Capital Markets.
- 8/17/2026 – Enovis had its price target lowered by Canaccord Genuity Group Inc. from $50.00 to $45.00. They now have a “buy” rating on the stock.
Insiders Place Their Bets
In related news, CEO Damien Mcdonald purchased 13,035 shares of the stock in a transaction dated Friday, September 4th. The shares were acquired at an average cost of $19.15 per share, with a total value of $249,620.25. Following the purchase, the chief executive officer directly owned 247,077 shares in the company, valued at $4,731,524.55. This trade represents a 5.57% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Oliver Engert purchased 2,660 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was bought at an average price of $18.80 per share, with a total value of $50,008.00. Following the acquisition, the insider directly owned 63,898 shares in the company, valued at approximately $1,201,282.40. This represents a 4.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 23,293 shares of company stock valued at $449,599. 2.90% of the stock is owned by corporate insiders.
The company’s offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies.
Read More
- Five stocks we like better than Enovis
- Amazon’s $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?
- Enlisting Capital: Wolfspeed’s Defense Deal
- Ag Equipment’s Recovery Trade Meets Washington’s Scrutiny
- The Pentagon’s $350 Million Quantum Push: Why IonQ Could Benefit More Than D-Wave
Receive News & Ratings for Enovis Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
